Chemical Structure (Doxazosin 01)
Doxazosin Tablet
Product Images NDC 0832-0356
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 0832-0356). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Table 3 (Doxazosin 02)
This text presents the results of three different studies evaluating the efficacy of doxazosin in treating benign prostatic hyperplasia (BPH). The studies measured the maximum flow rate (in mL/sec) and symptom scores of patients before and after treatment with either doxazosin or a placebo. Two of the studies titrated patients to a fixed maximum dose of doxazosin, while one titrated to the maximum dose of 8 ng. The results showed that doxazosin improved maximum flow rate and symptom scores in comparison to placebo, with statistically significant findings in some instances. The studies used different scoring systems for symptom evaluation.*
Figure 1 (Doxazosin 03)
This appears to be a table or graph displaying data related to a study comparing the effects of a treatment on symptoms and urinary flow rate in a group of 47 individuals over the course of several weeks. The results show changes from baseline measurements, with statistical significance noted for some comparisons. The treatment appears to involve titration of doxazosin up to a maximum dose of 8 mg.*
Principal Display Panel (1 mg Tablet Bottle Label)
Principal Display Panel (2 mg Tablet Bottle Label)
Principal Display Panel (4 mg Tablet Bottle Label)
Doxazosin tablets are a medication that is available in a pack of 100 tablets manufactured by GRS Laboratories. However, no specific information can be understood due to the incomplete and unclear text.*
Principal Display Panel (8 mg Tablet Bottle Label)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
